Drug Profile


Alternative Names: (+)-Alpha-Dihydrotetrabenazine; HTBZ

Latest Information Update: 30 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Adeptio Pharmaceuticals
  • Developer Adeptio Pharmaceuticals; University of Michigan
  • Class Quinolizines; Small molecules
  • Mechanism of Action Dopamine receptor antagonists; Vesicular monoamine transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Neurological disorders

Most Recent Events

  • 27 Jun 2017 University of Michigan and Adeptio Pharmaceuticals completes a phase I trial in Neurological disorders (In volunteers) in USA (PO) (NCT02844179)
  • 15 Sep 2016 Chemical structure information added
  • 01 Jul 2016 Phase-I clinical trials in Neurological disorders (In volunteers) in USA (PO) (NCT02844179)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top